SubHero Banner

Veklury®(remdesivir) – Expanded indication

April 25, 2022 - The FDA approved Gilead’s Veklury (remdesivir), for the treatment of coronavirus disease 2019 (COVID-19) in pediatric patients (≥ 28 days old and weighing ≥ 3 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, who are hospitalized, or not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death..

Download PDF